Visit Mounjaro in Quebec has raised a great many questions since its arrival on the Canadian market. Approved by Health Canada for the treatment of type 2 diabetes, this injectable medication (tirzepatide) is also being studied and used off-label for significant weight loss. Like any new medication, it’s important to understand it before discussing it with your doctor. This journalistic guide covers everything patients need to know: mechanism of action, approved indications, side effects, cost, alternatives, and recommended medical supervision.
On this page
- What is Mounjaro, and how does it work?
- Indications Approved by Health Canada
- Mounjaro and Weight Loss: What the Studies Say
- Side Effects and Precautions
- Cost, Coverage, and Availability in Quebec
- Comparison with Ozempic, Wegovy, and Other GLP-1 Drugs
- Why Structured Medical Follow-Up Is Essential
- Myths and misconceptions
- Frequently asked questions
What is Mounjaro?
Mounjaro is the brand name of the tirzepatide, a molecule developed by Eli Lilly. Unlike so-called GLP-1 drugs such as semaglutide—marketed under the brand names Ozempic and Wegovy—tirzepatide is a dual agonist: it acts simultaneously on two intestinal hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).
The Mechanism Explained Simply
- Stimulates the release of insulin by the pancreas when blood sugar levels rise.
- Reduces glucose production by the liver.
- Slows gastric emptying, causing the stomach to empty more slowly.
- Acts on the brain's satiety centers.
- Reduces feelings of hunger and increases feelings of fullness.
The injection is administered once a week, subcutaneously, in the abdomen, thigh, or arm. The initial dose is low (2.5 mg) and is gradually increased over several months to reduce gastrointestinal intolerance.
Approved dose ranges
| Bearing | Weekly dose | Recommended minimum duration |
|---|---|---|
| Introduction | 2.5 mg | 4 weeks |
| Initial Interview | 5 mg | 4 weeks |
| Gradual adjustment | 7.5 mg, then 10 mg | 4 weeks per stage |
| High doses | 12.5 mg, then 15 mg | Based on a medical evaluation |
To remember
- Mounjaro is the brand name for tirzepatide.
- It has a dual effect on GIP and GLP-1 receptors.
- It is administered by a weekly subcutaneous injection.
- A gradual titration over several months is required.
- It is approved in Canada for type 2 diabetes.
- A doctor's prescription is required.
Indications Approved by Health Canada
In Canada, the’official statement Tirzepatide is indicated for the treatment of type 2 diabetes in adults, as an adjunct to diet and appropriate physical activity, to improve glycemic control. The authorization was granted by Health Canada following an evaluation of the Phase III clinical trials in the SURPASS program.
What is officially stated
- Adult patients with inadequately controlled type 2 diabetes.
- As monotherapy or in combination with other antidiabetic medications.
- By prescription from a physician authorized to prescribe.
What Is Not Officially Stated in Canada
- Weight loss alone in a person without diabetes, which constitutes off-label use.
- Treatment of Type 1 Diabetes.
- Diabetic ketoacidosis.
- Pediatric use in children under 18 years of age, except in specific research settings.
Note: In the United States, a second version of tirzepatide is marketed under the name Zepbound, specifically for weight management. In Canada, this separate version is currently undergoing regulatory review. Patients seeking weight-loss treatment should therefore discuss this with their doctor to evaluate the available options that are consistent with current practice.
To remember
- The official indication in Canada is for type 2 diabetes.
- The medication is used as a supplement to lifestyle changes.
- Weight loss alone constitutes off-label use.
- Type 1 diabetes is not an indication.
- A separate version for weight is being considered in Canada.
- It is essential to discuss this with a doctor to determine the appropriate use.
Mounjaro and Weight Loss: What the Studies Say
Tirzepatide has been the subject of’large-scale clinical trials (the SURMOUNT programs) in overweight or obese adults without diabetes. Results published in leading journals such as the New England Journal of Medicine reported substantial average weight loss over 72 weeks, varying according to dosage and adherence to the treatment combined with a lifestyle intervention.
Orders of magnitude reported in the literature
| Weekly dose | Average weight loss observed |
|---|---|
| 5 mg | about 15 % of the initial weight |
| 10 mg | about 19 % of the initial weight |
| 15 mg | about 20 to 22 % of the initial weight |
These results are statistical averages derived from controlled trials. Individual responses may vary significantly. Furthermore, weight loss is sustainable only if the medication is combined with lasting changes in diet and physical activity, under medical supervision.
Are you wondering if a supervised medical approach is right for your situation? Our teams can discuss this with you. Learn more about our services, explore our solutions for businesses, choose the teleconsultation or Make an appointment online.
Side Effects and Precautions
Like any active drug, Mounjaro has a adverse reaction profile as documented by Health Canada. Most side effects are gastrointestinal in nature and tend to subside after the first few weeks, particularly during dose-escalation phases.
Common Side Effects
- Nausea.
- Vomiting.
- Diarrhea.
- Constipation.
- Abdominal pain.
- Loss of appetite.
- Reactions at the injection site.
Rarer but serious side effects
- Acute pancreatitis.
- Gallbladder problems, such as gallstones or cholecystitis.
- Acute kidney injury, often resulting from dehydration due to vomiting.
- Hypersensitivity reactions.
- Hypoglycemia associated with insulin or a sulfonylurea.
- Diabetic retinopathy may worsen in some cases.
Key Warnings
- Personal or family history of medullary thyroid cancer.
- Type 2 multiple endocrine neoplasia syndrome.
- History of pancreatitis.
- Severe renal or hepatic impairment.
- Pregnancy, breastfeeding, and the desire to become pregnant in the near future.
- Interactions with oral contraceptives: A non-oral method of contraception may be recommended during the first few weeks.
To remember
- Digestive side effects are common but often temporary.
- The risk of pancreatitis and biliary problems is rare but real.
- Thyroid-related warnings are important.
- Fluid intake should be monitored to protect the kidneys.
- Interactions with other antidiabetic medications are possible.
- Structured medical follow-up is essential.
Cost, Coverage, and Availability in Quebec
In Quebec, Mounjaro is available by prescription at community pharmacies. The monthly cost It varies depending on the dosage, packaging, and the pharmacy's markup, and can represent a significant investment for a patient without private insurance.
Insurance coverage
- The status of medications on the RAMQ Drug List is changing: please check with the RAMQ or your pharmacist.
- Many private insurance plans cover tirzepatide when it is prescribed for diagnosed type 2 diabetes.
- Coverage for weight loss alone is rarely accepted by public and private health insurance plans.
- The manufacturer offers a financial assistance program for eligible patients.
Availability
Supply shortages have been reported internationally due to increased demand for incretin mimetics. Patients are encouraged to plan ahead for their refills and to discuss temporary alternatives with their pharmacist in the event of a shortage.
Comparison with Ozempic, Wegovy, and Other GLP-1 Drugs
The market for drugs in the class GLP-1 and related substances has expanded. Here is a summary comparison of the molecules most commonly mentioned in Quebec.
| Trade Name | Molecule | Official Indication in Canada | Mechanism |
|---|---|---|---|
| Mounjaro | tirzepatide | Type 2 diabetes | Dual GIP/GLP-1 agonist |
| Ozempic | semaglutide | Type 2 diabetes | GLP-1 agonist |
| Wegovy | semaglutide (dose based on body weight) | Chronic Weight Management | GLP-1 agonist |
| Rybelsus | oral semaglutide | Type 2 diabetes | Oral GLP-1 agonist |
| Trulicity | dulaglutide | Type 2 diabetes | GLP-1 agonist |
| Victoza / Saxenda | liraglutide | Type 2 Diabetes / Weight | GLP-1 agonist (daily) |
The choice of one of these treatments does not depend solely on their average effectiveness: the side-effect profile, medical history, availability, cost, and insurance coverage all play a decisive role. This is exactly the kind of analysis a doctor can conduct with a patient, whether in person or via telemedicine.
Why Structured Medical Follow-Up Is Essential
A medication like tirzepatide is not something you should buy online without medical supervision. A prescription must be issued by a comprehensive medical evaluation, and regular follow-up helps prevent complications and adjust the dose based on the patient's actual response.
What Is Covered by Supervised Medical Care
- Initial evaluation: personal and family history, physical examination, blood tests.
- Discussion of realistic goals and alternatives.
- Dose selection and titration schedule.
- Monitoring of side effects and adjustments.
- Monitoring blood glucose control in patients with diabetes.
- Assessment of comorbidities: blood pressure, lipid levels, and kidney and liver function.
- Nutritional support and behavioral counseling.
- A shared decision regarding the duration of treatment and the terms of any potential discontinuation.
Our locations in Quebec offer in-person and telemedicine consultations for patients who wish to explore all of their metabolic management options. Our practice is based on Canadian guidelines for diabetes and weight management, and on a personalized approach that complies with professional regulations.
Myths and misconceptions
«Mounjaro is a miracle weight-loss drug.»
False. Tirzepatide has shown significant efficacy in clinical trials, but it does not work on its own. The most lasting results occur when it is combined with dietary changes, appropriate physical activity, and structured follow-up. Discontinuing the medication is often followed by weight regain if healthy habits are not established.
«You can buy Mounjaro online without a prescription.»
False. In Canada, tirzepatide is a prescription medication. Products sold without a prescription on third-party websites pose a high risk: counterfeits, incorrect dosages, lack of a cold chain, and lack of medical supervision. This can be dangerous and illegal.
«Mounjaro and Ozempic are identical.»
Nuanced. Both belong to the incretin mimetic class and share several clinical effects. However, tirzepatide acts on two receptors (GIP and GLP-1), whereas semaglutide acts on only one (GLP-1). Their efficacy and side effect profiles differ slightly. Only a doctor can determine which medication is most appropriate.
«Side effects always go away after a few weeks.»
Nuanced. Nausea and digestive problems often subside after the initial adjustment period, but some patients have difficulty tolerating the medication and must stop taking it. Others develop rarer side effects that require reevaluation. No medication is risk-free.
«Once you start, you have to keep doing it for the rest of your life.»
Nuanced. The duration of treatment depends on the medical condition, the treatment goals, and the individual’s response. For diabetes, treatment may be long-term. For weight management, discontinuing treatment is often followed by a partial return to previous habits if healthy habits have not been established. This decision should be made in consultation with your doctor—never on your own.
Frequently asked questions
Is Mounjaro covered by RAMQ?
Coverage changes as drugs are added to the Drug List. It is recommended that you check the RAMQ’s official website or consult your pharmacist to confirm the current status and conditions, particularly for patients with type 2 diabetes.
Can I get a prescription for Mounjaro through a telemedicine consultation?
A telemedicine consultation allows for a comprehensive medical evaluation. If the doctor determines that treatment is appropriate and safe in your specific situation, he or she may write a prescription. The decision is always based on your medical history, the physical exam, and any necessary tests—never on a simple request from the patient.
How long before I see results?
For blood glucose levels, the first effects are generally observed within weeks of starting treatment. For weight loss, the most pronounced benefits occur after several months of dose titration and stabilization at an effective dose, in combination with lasting lifestyle changes.
What happens if I stop taking the medication?
Discontinuation of tirzepatide may lead to a gradual rise in blood glucose levels in patients with diabetes and partial weight regain in individuals being treated for weight management. Discontinuation should be discussed with the doctor to plan next steps: continuing other treatments, or increasing nutritional monitoring or physical activity.
Is the Mounjaro safe for everyone?
No. Certain groups of people should avoid it or use it with great caution: those with a history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pancreatitis, pregnancy, breastfeeding, or severe kidney or liver failure. An individual medical evaluation is essential.
Can my employer cover this medication under their plan?
Some group health plans cover tirzepatide for patients with diabetes. Coverage for weight management remains less common. Companies interested in developing a metabolic health program for their employees can discuss this with our team via the page business services.
To discuss your situation with a professional, visit our page medical consultation.
Sources
- Health Canada — Summary of Decision Rationale for Mounjaro (tirzepatide) (hpr-rps.hres.ca)
- National Institute of Excellence in Health and Social Services (INESSS) — Advisory on Antihyperglycemic Agents (inesss.qc.ca)
- Quebec Health Insurance Board (RAMQ) — List of Medications (ramq.gouv.qc.ca)
- Diabetes Canada — Clinical Practice Guidelines (diabetes.ca)
- Eli Lilly Canada — Official Prescribing Information for Mounjaro (lilly.ca)
- New England Journal of Medicine — Once-Weekly Tirzepatide for the Treatment of Obesity (nejm.org)
- U.S. Food and Drug Administration (FDA) — Information on tirzepatide (fda.gov)
Omicron Clinic
Need to consult a doctor?
In-person or via telemedicine, anywhere in Quebec.
We accept insurance. Telemedicine consultations available 7 days a week. No family doctor required.
